Single agent phase II study of Forodesine (BCX1777) in the treatment of cutaneous T-Cell Lymphoma

Update Il y a 4 ans
Reference: EUCTR2007-002093-60

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL, stages IIb, III and IVa.


Inclusion criteria

  • Primary cutaneous T-cell lymphomas (CTCLs)